Marine n-3 Polyunsaturated Fatty Acids Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease Through Adiponectin-Ceramide Axis
Food Science and Human Wellness · 2025-11
DOI: 10.26599/fshw.2025.9250806 ↗Kurz gefasst
Fachartikel in der Zeitschrift Food Science and Human Wellness, 2025-11. Verfasst von Yan-fang Chen und 10 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Metabolic dysfunction-associated fatty liver disease (MAFLD), characterized as hepatic triglyceride accumulation, affects a quarter of the adult population worldwide, but limited therapeutic approaches are available in the treatment of MAFLD. It is widely believed that marine n-3 polyunsaturated fatty acids (PUFA) intervention could ameliorate MAFLD, however, the underlying mechanism remains elusive. Herein, in a case-control study, we identified serum C16:0-ceramide as a biomarker indicating MAFLD patients, which was negatively associated with n-3 PUFA levels in red blood cell phospholipids. The causality was confirmed by a randomized controlled trial (RCT), highlighting that supplemental n-3 PUFA had notable action in lowering serum C16:0-ceramide concentrations. The RCT indicated that serum adiponectin levels were negatively associated with serum C16:0-ceramide levels. An MAFLD model was established in mice fed a high-fat, high-cholesterol diet, and administration of n-3 PUFA increased adiponectin secretion and decreased hepatic C16:0-ceramide concentrations associated with reduced hepatic steatosis. In these mice, adiponectin administration contributed to decreased hepatic C16:0-ceramide concentrations and alleviated hepatic triglyceride accumulation through reduced de novo fatty acid synthesis and increased fatty acid β-oxidation. Furthermore, administration of C16:0-ceramide reversed the beneficial effects of n-3 PUFA in high-fat diet-induced MAFLD. This work reveals a novel mechanism, namely adiponectin-C16:0-ceramide axis, through which n-3 PUFA play a notable role in ameliorating MAFLD.
Zitieren
APA
Chen, Y., Fan, Z., Wang, Y., Liu, P., Cong, Y., Wang, Y., Zhao, T., Xu, T., Sinclair, A. J., Li, D., & Guo, X. (2025). Marine n-3 Polyunsaturated Fatty Acids Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease Through Adiponectin-Ceramide Axis. Food Science and Human Wellness. https://doi.org/10.26599/fshw.2025.9250806
Vancouver
Chen Y, Fan Z, Wang Y, Liu P, Cong Y, Wang Y, et al. Marine n-3 Polyunsaturated Fatty Acids Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease Through Adiponectin-Ceramide Axis. Food Science and Human Wellness. 2025. doi:10.26599/fshw.2025.9250806
BibTeX
@article{Chen2025,
author = {Chen, Yan-fang and Fan, Ze-kai and Wang, Yin-peng and Liu, Peng and Cong, Yi-xuan and Wang, Yuan and Zhao, Ting and Xu, Tong-cheng and Sinclair, Andrew J and Li, Duo and Guo, Xiao-fei},
title = {Marine n-3 Polyunsaturated Fatty Acids Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease Through Adiponectin-Ceramide Axis},
journal = {Food Science and Human Wellness},
year = {2025},
doi = {10.26599/fshw.2025.9250806}
}
EUVIMED